A Phase 2, Open-label Study of Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
A Phase 2, Open-label Study of Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
The purpose of the ATLAS study is to determine how patients with locally advanced unresectable or metastatic urothelial carcinoma respond to treatment with rucaparib.
Inclusion Criteria:
Exclusion Criteria:
La Jolla, California 92093, United States
Santa Monica, California 90404, United States
Norwich, Connecticut 06360, United States
Washington D.C., District of Columbia 20007, United States
Indianapolis, Indiana 46202, United States
Baltimore, Maryland 21201, United States
Hackensack, New Jersey 07601, United States
Albuquerque, New Mexico 87102, United States
New York, New York 10021, United States
Lyon, 69008, France
Saint-Herblain, 44805, France